Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2007-03-20
2007-03-20
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C424S142100, C435S326000, C435S346000, C530S389600, C530S388150
Reexamination Certificate
active
10073644
ABSTRACT:
Human monoclonal antibodies which bind specifically to Fc alpha receptor (CD89), including monoclonal antibodies which react specifically to Fc receptor for IgA of human effector cells are disclosed. The binding agents, e.g., antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.). For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can specifically lyse target cells.
REFERENCES:
patent: 5198342 (1993-03-01), Maliszewski
patent: 5328987 (1994-07-01), Maliszewski
patent: 5610057 (1997-03-01), Shen et al.
patent: 6018031 (2000-01-01), Shen et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 2381565 (2001-02-01), None
patent: 2408594 (2001-11-01), None
patent: 496818 (1999-06-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 98/02463 (1998-01-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 01/09186 (2001-02-01), None
patent: WO 01/09186 (2001-02-01), None
Ngo et al ., Protein Folding problem and Tertiary Structure prediction, 1994, Marz et al., (ed), Birkhauser, Boston, MA, pp. 433 and 492-495.
Rudikoff et al . Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Panka et al ., Proc Natl Acad Sci USA vol. 85 3080-3084 May 1988.
Amit et al., Science vol. 233 747-753 1986.
Monteiro, Renato C. et al. “Pathogenic significance of IgA receptor interactions in IgA nephropathy.”TRENDS in molecular Medicine8(10):464-8 (Oct. 2002).
Morgan, A. et al. “The N-terminal end of the CH2domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcyRI and FcyRIII binding”Immunology86:319-24 (1995).
Hudson Debra
van de Winkel Jan G. J.
van Dijk Marcus A.
Belyavskyi Michail
Chan Christina
Lahive & Cockfield LLP
Medarex Inc.
Remillard, Esquire Jane E.
LandOfFree
Human monoclonal antibodies to FC alpha receptor (CD89) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies to FC alpha receptor (CD89), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to FC alpha receptor (CD89) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3785691